Data completeness
2/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONSENSI is an oral tablet NDA approved by the FDA on May 31, 2018, currently in peak commercial lifecycle. The mechanism of action, pharmacologic class, and therapeutic indication are not publicly disclosed in available data. Patient population cannot be determined without indication information.
Peak11.6 years to LOE
Limited commercial hiring signals detected with only 3 linked roles; product may have narrow market focus or mature sales infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CONSENSI shows minimal career activity with only 3 linked job openings, heavily skewed toward digital marketing and social media roles rather than traditional pharma functions. This hiring pattern suggests either a small commercial footprint or a digitally-focused go-to-market strategy for Purple Biotech.
SEO Marketing ManagerSocial Media (Working Student)
Worked on CONSENSI at Purple Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.